<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01103011</url>
  </required_header>
  <id_info>
    <org_study_id>ND0611/001</org_study_id>
    <nct_id>NCT01103011</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetic Profile of Levodopa Administered With Continuous Administration of ND0611</brief_title>
  <official_title>A Phase I, Single Center, Blinded, Controlled Study Evaluating Safety, Tolerability and Pharmacokinetic Profile of Levodopa Following Repeated Administration of Oral Levodopa/Carbidopa and Continuously Delivered ND0611</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeuroDerm Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NeuroDerm Ltd.</source>
  <brief_summary>
    <textblock>
      The study hypothesis is that continuous ND0611 increases the bioavailability of levodopa and&#xD;
      therefore the levodopa area-under-the-concentration-curve values, half-life, and trough&#xD;
      concentrations The study will help determining the safety and tolerability of ND0611 and&#xD;
      determine the pharmacokinetic profile of levodopa following multiple oral dosing of&#xD;
      levodopa/carbidopa (LD/CD) and continuous delivery of ND0611&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <description>Safety and tolerability:&#xD;
Adverse event reporting&#xD;
Discontinuation of the treatment due to adverse event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <description>Pharmacokinetic profile of plasma LD and CD:&#xD;
Primary endpoint: tÂ½&#xD;
Secondary endpoints: through levels, Cmax, Tmax, AUC</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>ND0611 dose 1, ND0611 dose 2, placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ND0611</intervention_name>
    <description>Continuous delivery of ND0611</description>
    <arm_group_label>ND0611 dose 1, ND0611 dose 2, placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ND0611</intervention_name>
    <description>Solution of ND0611 delivered continuously</description>
    <arm_group_label>ND0611 dose 1, ND0611 dose 2, placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy Caucasian males between 18 and 50 years (inclusive) of age&#xD;
&#xD;
          -  Normal body weight&#xD;
&#xD;
          -  Subjects with negative urinary drugs of abuse, HIV, Hepatitis B or Hepatitis C&#xD;
             serology tests&#xD;
&#xD;
          -  Subjects must be able to adhere to the protocol requirements&#xD;
&#xD;
          -  Subjects must provide written informed consent to participate in the study.&#xD;
&#xD;
          -  Haemoglobin level &gt;12.5 mg /dl&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of significant psychiatric disorder, neurological diseases or sleep disorders&#xD;
&#xD;
          -  History of significant systemic diseases, by medical history or tests performed during&#xD;
             screening examinations&#xD;
&#xD;
          -  Clinically significant laboratory tests at screening&#xD;
&#xD;
          -  History of drug or alcohol abuse.&#xD;
&#xD;
          -  Allergy to levodopa, carbidopa or any inactive component of the test formulation.&#xD;
&#xD;
          -  Subjects with dark skin&#xD;
&#xD;
          -  Subjects with skin diseases or neoplasms&#xD;
&#xD;
          -  Subjects with narrow-angle glaucoma&#xD;
&#xD;
          -  Subjects with significant allergic response to other drugs.&#xD;
&#xD;
          -  Subject with known atopic disorders&#xD;
&#xD;
          -  Known allergy or hypersensitivity to adhesive tapes.&#xD;
&#xD;
          -  Use of any prescription or over-the-counter (OTC) medications&#xD;
&#xD;
          -  Subjects who donated blood or received blood, in the last 3 months&#xD;
&#xD;
          -  Participation in another clinical trial in the last 30 days&#xD;
&#xD;
          -  Subjects which do not have the ability to communicate well or will not adhere to the&#xD;
             protocol procedures&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <study_first_submitted>April 12, 2010</study_first_submitted>
  <study_first_submitted_qc>April 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2010</study_first_posted>
  <last_update_submitted>October 3, 2010</last_update_submitted>
  <last_update_submitted_qc>October 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2010</last_update_posted>
  <responsible_party>
    <name_title>Sheila Oren MD, VP Clinical and Regulatory Affairs</name_title>
    <organization>Neuroderm, ltd.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

